GUGGENHIME ANDREW, PRES, reported a transaction classified as exercise at Vaxcyte, Inc. involving 8000.000000 shares for an estimated $42800.00. Reported holdings after the transaction were 117491.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
PRESIDENT AND CFO
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted May 17, 2024.
The price reported is a weighted-average price. The shares were sold at prices ranging from $85.54 to $86.455. The reporting person will provide upon request to the SEC, the issuer or security holder…
issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $86.58 to $87.545. The reporting person will provide upon request to the SEC, the issuer or security holder…
The price reported is a weighted-average price. The shares were sold at prices ranging from $87.58 to $87.85. The reporting person will provide upon request to the SEC, the issuer or security holder o…
1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.
0 other filings
0 recent txs